According to an EvaluatePharma study, two-thirds of all drug launches failed to meet pre-launch expectations in sales their first year on the market.
Selling is hard, there's no arguing that. To meet this challenge head-on, most industries employ the five C's method of sales with great success.
There's no denying that the right pharma industry is a constantly changing, fluid environment and it's often difficult to find your rightful place within the industry.
HUB services have been around for about a decade now. In the past, pharma companies were beginning to recognize that there was more involved in bringing new drugs to the market than just getting the dosages into distribution channels.
In addition to more common concerns, pharma was experiencing more and more restrictions from payers. Particularly, from the Prior Authorization (PA) form. This was very time-consuming and had to be filled out ahead of time by the prescriber.
Therefore, the HUBs focused more on reimbursement and prescriber support. Initially run in-house, as the use of HUBs broadened "prescriber support" to "patient support," third-party HUB service providers began to enter the market.
To date, this vertical industry shows no sign of slowing growth.
Whether you’re knowledgeable on Clinical Trials and the process that goes into it or not, it's correctly assumed that the work is far from light. There are four phases for each study conducted that tells the plot of the story, but doesn’t dive into the supporting elements within.
A key component of any company is sales. The product or service must be sold in order for the business to continue running their business.
Pharmaceutical companies aren't immune to this requirement. This is why they run advertisements online, on the radio, on billboards, and on television. Yet, it's not only individuals with conditions and diseases that they need to expose their product to.
Pharmaceutical companies also need to convince doctors that their drugs work and could be beneficial to patients. It's for this reason that pharmaceutical representatives are sent out into the field, to speak with healthcare officials, and showcase the newest drug developments.
Driving pharma to the cloud is value-driven and geared to patients who take active roles in their healthcare. Specifically, those who want information at their fingertips. Instead, of waiting for it to trickle down through the maze of doctors, tests, and procedures.
It's also driven by constantly changing health care regulations, finances, digital initiation, integration, and individual companies that want more efficient ways to manage their patient data.
Will public clouds be too risky? Will private clouds be safe? What about a hybrid of the two?
While you're analyzing the risks and benefits that the cloud might bring to your organization, consider the network availability. Performance and security are key players in those driving forces that help enterprises choose a cloud infrastructure.
Anupam Nandwana | January 9, 2018
Swapan Kumar Manna | May 20, 2018
Avirup Basu | June 7, 2018
Anupam Nandwana | October 6, 2017
Anupam Nandwana | March 8, 2018